colchicine has been researched along with Cytokine Release Syndrome in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 9 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdeen, S; Abu-Fanne, R; Bdeir, K; Cines, DB; Heyman, SN; Higazi, AA; Higazi, M; Maraga, E | 1 |
| Aboshanab, KM; Ismail, NSM; Kamel, NA; Yahia, IS | 1 |
| Al-Gareeb, AI; Al-Kuraishy, HM; Al-Niemi, MS; Hussien, NR | 1 |
| Abbas, Y; Ali, R; Allergini, P; Ashraf, S; Asif, H; Farooq, U; Ghafoor, A; Gillani, SY; Haroon, MZ; Irshad, R; Khalil, AT; Khan, A; Khan, S; Livingstone, S; Malik, S; Masood, A; Mehmood, Z; Nigar, R; Pascual-Figal, DA; Riva, A; Togni, S; Ujjan, ID; Zeb, S | 1 |
| Azad, KAK; Datta, PK; Faruq, I; Haque, M; Hasan, P; Islam, K; Mahmud, R; Mallik, U; Miah, T; Rahman, M; Rahman, MM; Ratul, RH; Sharif, M | 1 |
| Dagna, L; Della-Torre, E; Della-Torre, F; Kusanovic, M; Ramirez, GA; Scotti, R; Tresoldi, M | 1 |
| Mansouri, D; Mansouri, N; Marjani, M; Tabarsi, P; von Garnier, C | 1 |
| Burrage, DR; Koushesh, S; Sofat, N | 1 |
| Ferrara, F; Vitiello, A | 1 |
4 review(s) available for colchicine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Potential Role of Colchicine in Combating COVID-19 Cytokine Storm and Its Ability to Inhibit Protease Enzyme of SARS-CoV-2 as Conferred by Molecular Docking Analysis.
Topics: Colchicine; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Cytokine Release Syndrome; Humans; Molecular Docking Simulation; SARS-CoV-2 | 2021 |
Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature.
Topics: Administration, Oral; Adult; Colchicine; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Gout; Humans; Male; SARS-CoV-2; Treatment Outcome | 2021 |
Immunomodulatory Drugs in the Management of SARS-CoV-2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Colchicine; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Cytokines; Female; Humans; Hydroxychloroquine; Immunomodulation; Janus Kinase Inhibitors; Middle Aged; Pandemics; Pneumonia, Viral; Risk Factors; SARS-CoV-2; Tumor Necrosis Factor-alpha | 2020 |
Colchicine and SARS-CoV-2: Management of the hyperinflammatory state.
Topics: Colchicine; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Humans; SARS-CoV-2; Tubulin Modulators | 2021 |
3 trial(s) available for colchicine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Divergent impacts of tocilizumab and colchicine in COVID-19-associated coagulopathy: the role of alpha-defensins.
Topics: Aged; alpha-Defensins; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Blood Coagulation; Colchicine; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Female; Fibrin Fibrinogen Degradation Products; Humans; Interleukin-6; Male; Middle Aged; Neutrophils | 2022 |
Colchicine anti-inflammatory therapy for non-intensive care unit hospitalized COVID-19 patients: results from a pilot open-label, randomized controlled clinical trial.
Topics: Anti-Inflammatory Agents; Colchicine; COVID-19 Drug Treatment; Cytokine Release Syndrome; Hospitalization; Humans; SARS-CoV-2; Treatment Outcome | 2022 |
Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial.
Topics: Bangladesh; Clinical Deterioration; Colchicine; COVID-19 Drug Treatment; Cytokine Release Syndrome; Humans; Respiratory Distress Syndrome; SARS-CoV-2; Treatment Outcome | 2022 |
2 other study(ies) available for colchicine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Colchicine in the management of Covid-19: With or lieu of evidence.
Topics: Anti-Inflammatory Agents; Colchicine; COVID-19; Cytokine Release Syndrome; Cytokines; Humans; SARS-CoV-2 | 2021 |
Treating COVID-19 with colchicine in community healthcare setting.
Topics: Acetaminophen; Anti-Inflammatory Agents; Azithromycin; Betacoronavirus; Cohort Studies; Colchicine; Community Health Services; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Fever; Gene Expression; Humans; Immunity, Innate; Inflammasomes; Intensive Care Units; Interleukin-1; Interleukin-6; Italy; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severe Acute Respiratory Syndrome; Time Factors | 2020 |